EGFR and neoplasm: It has been determined that the PD-L1 expression varies during tumor progression due to communication between the tumor and the cells of immune system—the action of antitumor therapy, for example—against a background of the use of tyrosine kinase inhibitors that suppress the activity of EGFR or ALK [4].